Long term physical sequelae after adult-onset cancer

被引:44
作者
Fosså S.D. [1 ,2 ]
Vassilopoulou-Sellin R. [3 ]
Dahl A.A. [1 ,2 ]
机构
[1] Cancer Clinic, Department of Clinical Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello
[2] University of Oslo, Oslo
[3] M.D. Anderson Cancer Centre, University of Texas, Houston, TX
关键词
Adult-onset; Guidelines; Long-term effects; Patient care plan; Transitional research;
D O I
10.1007/s11764-007-0039-5
中图分类号
学科分类号
摘要
With two thirds of cancer patients living for at least 5 years, clinical research has increasingly focused on the long-term health of cancer survivors. Contrary to the amount of knowledge on long-term consequences observations on late effects after childhood cancer in adult-onset cancer are sparse. Only limited literature is available recommending guidelines for long-term follow-up of cancer patients and their implementation in the delivery of health care. In this review we summarize updated knowledge on the most frequent physical long-term effects after adult-onset cancer, and we discuss how these findings can be implemented in life-long follow-up programs of cancer survivors. Second cancer, cardiovascular disorders and gonadal dysfunction are the most common physical late effects along with fatigue. Common age-related co-morbidity reduces physical function in long-term cancer survivors. Cancer survivors have to be informed about their risk of late effects, and how to prevent them by life style adjustments and, if indicated, regular health care visits. Studies on late effects after cancer treatment should be combined with translational research in order to improve our understanding of pathophysiological mechanisms of long-term effects. The effectiveness of therapeutic interventions for reduction of these treatment sequelae in long-term survivors need to be investigated in randomized trials. Guidelines for life-long follow-up of cancer survivors should be established and will form the first step is the design of an individual life-long cancer survivor care plan. © 2007 Springer Science+Business Media, LLC.
引用
收藏
页码:3 / 11
页数:8
相关论文
共 101 条
[71]  
Mykletun A., Dahl A.A., Haaland C.F., Bremnes R., Dahl O., Klepp O., Wist E., Fossa S.D., Side-effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer, J Clin Oncol, 23, pp. 3061-8, (2005)
[72]  
Oldenburg J., Sm K., Cvancarova M., Lothe R.A., Fossa S.D., Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors, J Clin Oncol, 25, pp. 708-14, (2007)
[73]  
Tannock I.F., Ahles T.A., Ganz P.A., Van Dam F.S., Cognitive impairment associated with chemotherapy for cancer: Report of a workshop, J Clin Oncol, 22, pp. 2233-9, (2004)
[74]  
Bradley J., Graham M.V., Winter K., Purdy J.A., Komaki R., Roa W.H., Ryu J.K., Bosch W., Emami B., Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma, Int J Radiat Oncol Biol Phys, 61, pp. 318-28, (2005)
[75]  
Stensvold E., Aass N., Gladhaug I., Stenwig A.E., Claussen O.P., Fossa S.D., Erroneous diagnosis of pancreatic cancer after radiotherapy of testicular cancer, Eur J Surg Oncol, 30, pp. 352-5, (2004)
[76]  
Maduro J.H., Pras E., Willemse P.H.B., De Vries E.G.E., Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer, Cancer Treat Rev, 29, pp. 471-88, (2003)
[77]  
Green J., Kirwan J., Tierney J., Vale C., Symonds P., Fresco L., Williams C., Collingwood M., Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix, Cochrane Database Syst Rev, 20, 3, (2005)
[78]  
Lundby L., Krogh K., Jensen V.J., Gandrup P., Qvist N., Overgaard J., Laurberg S., Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer, Dis Colon Rectum, 45, pp. 1343-9, (2005)
[79]  
Dearnaley D.P., Sydes M.R., Graham J.D., Aird E.G., Bottomley D., Cowan R.A., Huddart R.A., Jose C.C., Matthews J.H., Millar J., Et al., Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial, Lancet Oncol, 8, pp. 475-87, (2007)
[80]  
Carver J.R., Shapiro C.L., Ng A., Jacobs L., Schwartz C., Virgo K.S., Hagerty K.L., Somerfield M.R., Vaughn D.J., ASCO Cancer Survivorship Expert Panel, J Clin Oncol, 25, pp. 3991-4008, (2007)